.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
VISUAL II was a multicentre phase 3 randomized, placebo-controlled trial evaluating adalimumab in adults with inactive, non-infectious intermediate, posterior or panuveitis controlled with systemic corticosteroids. Patients were assigned to adalimumab or placebo while prednisone was tapered. Treatment failure occurred significantly less often in the adalimumab group, and time to treatment failure was substantially prolonged. The result supports TNF inhibition as an effective steroid-sparing strategy for patients whose posterior non-infectious uveitis is controlled but remains at risk of recurrence when corticosteroids are reduced. For HCPs, the study illustrates the importance of moving beyond chronic steroid dependence when longer-term immunosuppression is needed. Patient selection must still consider infection screening, tuberculosis risk, vaccination, systemic comorbidity and monitoring. The trial is directly relevant to AIOC's uvea programme and its emphasis on biologic therapies for non-infectious uveitis.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
VISUAL II was a multicentre phase 3 randomized, placebo-controlled trial evaluating adalimumab in adults with inactive, non-infectious intermediate, posterior or panuveitis controlled with systemic corticosteroids. Patients were assigned to adalimumab or placebo while prednisone was tapered. Treatment failure occurred significantly less often in the adalimumab group, and time to treatment failure was substantially prolonged. The result supports TNF inhibition as an effective steroid-sparing strategy for patients whose posterior non-infectious uveitis is controlled but remains at risk of recurrence when corticosteroids are reduced. For HCPs, the study illustrates the importance of moving beyond chronic steroid dependence when longer-term immunosuppression is needed. Patient selection must still consider infection screening, tuberculosis risk, vaccination, systemic comorbidity and monitoring. The trial is directly relevant to AIOC's uvea programme and its emphasis on biologic therapies for non-infectious uveitis.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
